Sector News

Thermo Fisher shoulders into gene therapy manufacturing with $1.7B deal for Brammer

March 26, 2019
Life sciences

With gene therapies becoming a hot growth area, CDMOs are figuring out how to get a bigger piece of the market. Thermo Fisher Scientific decided to buy its way in, agreeing to pay $1.7 billion to get viral vector producer Brammer Bio.

The cash deal, slated to close by the end of the second quarter, will see Waltham, Massachusetts-based Thermo Fisher picking up manufacturing locations in Massachusetts and Florida, along with 600 employees. Brammer is owned by Ampersand Capital Partners.

Cambridge-based Brammer Bio, which has undertaken 100 projects, is expected to produce $250 million in revenue this year and outrun the market growth rate of 25% for the midterm, the companies said. Thermo Fisher says the deal should add about $0.10 per share in the first full year of ownership.

Michel Lagarde, president of Thermo Fisher’s pharma services, said the combination of the two companies can only strengthen both their positions in the burgeoning field.

Novartis, Gilead and Spark Therapeutics already have gene therapies approved in the U.S., and several more of the potential cures are wending their way through the development and approval processes. Novartis is looking for a second gene therapy approval soon for spinal muscular atrophy treatment, Zolgensma.

Many gene therapy biotechs are committing money to building their own specialized manufacturing facilities while also looking for redundancy from contractors. Swiss CDMO giant Lonza expanded its offerings last year when it opened a 300,000 square foot facility in the Houston, Texas, suburb of Pearland, which it claims is the largest dedicated cell-and-gene-therapy manufacturing facility in the world.

Brammer saw the potential early. It was formed in 2016 through the merger of Brammer Biopharmaceuticals and Alachua, Florida-based Florida Biologix, saying at the time it would invest about $50 million in a 50,000-square-foot facility in Lexington for the production of late-stage and commercial-scale viral vector and cell-based therapies.

It also bought a 67,000-square-foot manufacturing facility in Cambridge from Biogen in 2016. A spokesperson said in an email today that the Florida site includes preclinical and clinical viral vector manufacturing, process and analytical development laboratories and quality control laboratories. The facilities in Cambridge and Lexington support commercial-ready cGMP manufacturing of viral vectors.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

October 23, 2021

Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch

Life sciences

As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.

October 23, 2021

GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody

Life sciences

The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.

October 23, 2021

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.

Send this to a friend